CDKN2A and cancer: To our knowledge, this cohort study with the largest sample size determines the association of CDKN2A ALT with clinical outcomes and response to ICIs among pan-cancer patients treated or not treated with immunotherapy to provide a reference for better personalizing therapy for CDKN2A ALT cancer patients.